Večerić-Haler Željka, Romozi Karmen, Antonič Manja, Benedik Miha, Ponikvar Jadranka Buturović, Ponikvar Rafael, Knap Bojan
Department of Nephrology, University Medical Center Ljubljana, Ljubljana, Slovenia.
Ther Apher Dial. 2016 Jun;20(3):261-6. doi: 10.1111/1744-9987.12434.
Management of secondary hyperparathyroidism (SHPT) in dialysis population includes the use of active vitamin D forms, among which paricalcitol was shown to be more effective at reducing parathyroid hormone (PTH) concentrations. A prospective randomized study comparing the effectiveness and safety of peroral paricalcitol and calcitriol in suppressing PTH concentrations in 20 hemodialysis patients was performed comparing the influence of agents on PTH suppression, calcium (Ca) and phosphate (P) level and calcium-phosphorus product (C×P). The study was performed in an "intent to treat" manner with primary end point in reduction of PTH level in the target area of 150 > PTH < 300 ng/L after 3 months. At the time point 3 months after therapy induction paricalcitol and calcitriol were equally efficient at correcting PTH levels, with paricalcitol showing significantly less calcemic effect than calcitriol.
透析人群继发性甲状旁腺功能亢进（SHPT）的管理包括使用活性维生素D制剂，其中帕立骨化醇在降低甲状旁腺激素（PTH）浓度方面显示出更有效。一项前瞻性随机研究对20例血液透析患者口服帕立骨化醇和骨化三醇在抑制PTH浓度方面的有效性和安全性进行了比较，同时比较了药物对PTH抑制、钙（Ca）和磷（P）水平以及钙磷乘积（C×P）的影响。该研究以“意向性治疗”方式进行，主要终点是3个月后将PTH水平降低至150＞PTH＜300 ng/L的目标范围。在治疗开始3个月的时间点，帕立骨化醇和骨化三醇在纠正PTH水平方面同样有效，且帕立骨化醇的血钙升高作用明显低于骨化三醇。
